Cargando…
The Tumor Microenvironment in Colorectal Cancer Therapy
The current standard-of-care for metastatic colorectal cancer (mCRC) includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, even though the addition of anti-angiogenic agents to backbone chemotherapy provides little benefit for overall surviv...
Autores principales: | Pedrosa, Leire, Esposito, Francis, Thomson, Timothy M., Maurel, Joan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721633/ https://www.ncbi.nlm.nih.gov/pubmed/31416205 http://dx.doi.org/10.3390/cancers11081172 |
Ejemplares similares
-
Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients
por: Oliveres, Helena, et al.
Publicado: (2021) -
Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer
por: Gallo, Gaetano, et al.
Publicado: (2021) -
TGFβ and the Tumor Microenvironment in Colorectal Cancer
por: Waldner, Maximilian J., et al.
Publicado: (2023) -
The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
por: Mosteiro, Alejandra, et al.
Publicado: (2022) -
Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer
por: Plundrich, Dorothea, et al.
Publicado: (2022)